PE20110329A1 - Agonistas del receptor acoplado a la proteina g piperidinilo - Google Patents

Agonistas del receptor acoplado a la proteina g piperidinilo

Info

Publication number
PE20110329A1
PE20110329A1 PE2011000013A PE2011000013A PE20110329A1 PE 20110329 A1 PE20110329 A1 PE 20110329A1 PE 2011000013 A PE2011000013 A PE 2011000013A PE 2011000013 A PE2011000013 A PE 2011000013A PE 20110329 A1 PE20110329 A1 PE 20110329A1
Authority
PE
Peru
Prior art keywords
methyl
protein
phenoxy
propyl
piperidinyl
Prior art date
Application number
PE2011000013A
Other languages
English (en)
Spanish (es)
Inventor
Lisa Sarah Bertram
Mathew Colin Thor Fyfe
Revathy Perpetua Jeevaratnam
John Keily
Thomas Martin Krulle
Chrystelle Marie Rasamison
Colin Peter Sambrook-Smith
Simon Andrew Swain
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0812646A external-priority patent/GB0812646D0/en
Priority claimed from GB0812622A external-priority patent/GB0812622D0/en
Priority claimed from GB0902391A external-priority patent/GB0902391D0/en
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of PE20110329A1 publication Critical patent/PE20110329A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PE2011000013A 2008-07-10 2009-07-10 Agonistas del receptor acoplado a la proteina g piperidinilo PE20110329A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0812646A GB0812646D0 (en) 2008-07-10 2008-07-10 Compounds
GB0812622A GB0812622D0 (en) 2008-07-10 2008-07-10 Compounds
GB0902391A GB0902391D0 (en) 2009-02-13 2009-02-13 Compounds

Publications (1)

Publication Number Publication Date
PE20110329A1 true PE20110329A1 (es) 2011-06-03

Family

ID=41070447

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000013A PE20110329A1 (es) 2008-07-10 2009-07-10 Agonistas del receptor acoplado a la proteina g piperidinilo

Country Status (15)

Country Link
US (1) US20110269734A1 (enExample)
EP (1) EP2321297A1 (enExample)
JP (1) JP2011527331A (enExample)
KR (1) KR20110036609A (enExample)
CN (1) CN102083813A (enExample)
AU (1) AU2009269772A1 (enExample)
CA (1) CA2728042A1 (enExample)
CL (1) CL2011000051A1 (enExample)
EA (1) EA201170151A1 (enExample)
IL (1) IL209978A0 (enExample)
MA (1) MA32467B1 (enExample)
MX (1) MX2011000060A (enExample)
PE (1) PE20110329A1 (enExample)
WO (1) WO2010004343A1 (enExample)
ZA (1) ZA201008955B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110053949A1 (en) * 2008-04-17 2011-03-03 Pfizer Inc. 4-[3-(aryloxy)benzylidene]-3-methyl piperidine aryl carboxamide compounds useful as faah inhibitors
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
SG176015A1 (en) 2009-05-13 2011-12-29 Gilead Sciences Inc Antiviral compounds
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8293729B2 (en) 2009-06-24 2012-10-23 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
US8481731B2 (en) 2009-06-24 2013-07-09 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
JP2013522279A (ja) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連状態の治療で用いるgpr119作動薬とddp−iv阻害薬リナグリプチンの組合せ
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
AR083904A1 (es) 2010-11-18 2013-04-10 Prosidion Ltd Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
US8957062B2 (en) 2011-04-08 2015-02-17 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
EP2720544B1 (en) 2011-06-16 2016-12-21 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
HRP20180237T4 (hr) 2011-09-16 2020-12-11 Gilead Pharmasset Llc Metode za liječenje hcv-a
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013048916A1 (en) 2011-09-30 2013-04-04 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
EP2771000B1 (en) 2011-10-24 2016-05-04 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as gpr119 agonists
CA2855009C (en) 2011-11-15 2019-07-09 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as gpr119 agonists
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений
WO2018068295A1 (en) * 2016-10-14 2018-04-19 Merck Sharp & Dohme Corp. ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE
JP2022552655A (ja) * 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
AU2022279234B2 (en) 2021-05-21 2025-08-28 Gilead Sciences, Inc. Pentacyclic derivatives as zika virus inhibitors
JP7723119B2 (ja) 2021-05-21 2025-08-13 ギリアード サイエンシーズ, インコーポレイテッド ジカウイルス感染症の治療のための四環系化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006264649A1 (en) * 2005-06-30 2007-01-11 Prosidion Limited GPCR agonists

Also Published As

Publication number Publication date
MX2011000060A (es) 2011-02-22
EP2321297A1 (en) 2011-05-18
JP2011527331A (ja) 2011-10-27
WO2010004343A1 (en) 2010-01-14
KR20110036609A (ko) 2011-04-07
IL209978A0 (en) 2011-02-28
CN102083813A (zh) 2011-06-01
EA201170151A1 (ru) 2011-08-30
AU2009269772A1 (en) 2010-01-14
MA32467B1 (fr) 2011-07-03
CA2728042A1 (en) 2010-01-14
ZA201008955B (en) 2011-08-31
US20110269734A1 (en) 2011-11-03
CL2011000051A1 (es) 2012-03-16

Similar Documents

Publication Publication Date Title
PE20081659A1 (es) Agonistas de gpcr
PE20081849A1 (es) Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
PE20110598A1 (es) Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
PE20120218A1 (es) Compuestos para el tratamiento de trastornos metabolicos
PE20090449A1 (es) Agonistas de receptor acoplado a proteina g gpr119 de piridona
PE20120620A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20091901A1 (es) Activadores de glucoquinasa
AR065794A1 (es) Pirimidodiazepinas sustituidas
PE20081636A1 (es) Inhibidores de antranilamida para aurora quinasa
PE20110237A1 (es) Derivados de ciclohexilamida como antagonistas del receptor del factor de liberacion de corticotropina (crf-1)
PE20090157A1 (es) Derivados de pirimidinona como moduladores del receptor acoplado a proteina g 119 (gpr119)
PE20081878A1 (es) Compuestos derivados de 1-(4-hidroxifenil sustituido)-4-ol-indazol
PE20090815A1 (es) Compuesto de amida
DK2035379T3 (da) Inhibitorer af 11-beta-hydroxysteroiddehydrogenase 1
PE20080056A1 (es) Derivados de cromencarboxamida como antagonistas del receptor s1p1
PE20070136A1 (es) COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1
PE20090814A1 (es) Cis-imidazolinas quirales
PE20081404A1 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona y procesos para su preparacion
PE20140868A1 (es) Antagonistas trpm8 y su uso en tratamientos
PE20110341A1 (es) COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA
PE20080676A1 (es) Derivados de indol como antagonistas del receptor de glucagon
DK2021337T3 (da) Inhibitorer af 11-beta-hydroxysteroid-dehydrogenase-1
PE20080519A1 (es) Derivados de ester isopropilico del acido 4-[5-metoxi-6-(2-metil-6-[1,2,4]triazol-1-il-piridin-3-ilamino)pirimidin-4-iloxi]-piperidina-1-carboxilico y sus composiciones farmaceuticas
PE20121045A1 (es) Agonista de gpr119
PE20090592A1 (es) Nuevos derivados de piperazina-amida

Legal Events

Date Code Title Description
FX Voluntary withdrawal